MEDIA ADVISORY, Aug. 31, 2006 (PRIMEZONE) --
What: Michael Becker, president and CEO of Cytogen Corporation (CYTO) and former New York City Mayor Rudy Giuliani will preside over the opening bell to help kick off Prostate Cancer Awareness Month and the fifth annual "Screen, Stage and Support" campaign to promote prostate cancer education. "Screen, Stage and Support" is the annual awareness campaign sponsored by Cytogen to help patients, families and caregivers to recognize the important role that proper screening, diagnosis, treatment and support can have for anyone affected by prostate cancer. Leading prostate cancer patient organizations joining in the opening bell ceremony are the American Cancer Society, the American Urological Association, the Prostate Cancer Foundation and UsTOO International. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Friday September 1st, 2006 at 9:30 a.m. EDT Contacts: Kim Angelastro Berry & Company (212) 253-8881 (912) 441-8263 (cell) firstname.lastname@example.org NASDAQ MarketSite: Stephanie Lowenthal; 646.441.5220
The opening bell is available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Stephanie Lowenthal at (646) 441-5220.
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Cytogen Corporation (CYTO):
Founded in 1980, Cytogen Corporation of Princeton, NJ, is a biopharmaceutical company dedicated to improving the lives of patients with cancer by acquiring, developing and commercializing innovative molecules targeting the sites and stages of cancer progression. Cytogen's marketed products include QUADRAMET(R) (samarium Sm-153 lexidronam injection), PROSTASCINT(R) (capromab pendetide) kit for the preparation of Indium In-111 capromab pendetide, and SOLTAMOX(TM) (tamoxifen citrate, oral solution 10mg/5mL) in the United States. Cytogen's development pipeline consists of CYT-500, a therapeutic radiolabeled antibody targeting prostate-specific membrane antigen (PSMA), a protein highly expressed on the surface of prostate cancer cells and the neovasculature of solid tumors. Cytogen also has exclusive United States marketing rights to COMBIDEX(R) (ferumoxtran-10) for all applications, and the exclusive right to market and sell ferumoxytol (previously Code 7228) for oncology applications in the United States. Full prescribing information for the Company's products is available at www.cytogen.com or by calling 800-833-3533. For more information, please visit the Company's website at www.cytogen.com
In This StoryNDAQ
Nasdaq Press Center
Read the latest press releases, request a press kit, and get in touch with our press team.